medication and systemic lupus erythematosus (SLE) Archives

Abstract Number: 2584 • ACR/ARHP Annual Meeting 2017
Apremilast in Patients with Lupus Rashes
Robert S. Katz, Rush University Medical Center, Chicago, IL
Background/Purpose: Apremilast has been approved by the FDA for treatment of psoriasis and psoriatic arthritis. Because side effects are few, we decided to use it…
Abstract Number: 903 • ACR/ARHP Annual Meeting 2014
Poor Adherence to Medications for Systemic Lupus Erythematosus Predicts Higher Health Care Utilization in U.S. Medicaid Beneficiaries
Jinoos Yazdany¹, Candace H. Feldman², Hongshu Guan³ and Karen H. Costenbader⁴, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Immunosuppressive and antimalarial drugs improve outcomes in systemic lupus erythematosus (SLE), including reducing disease activity, damage and mortality. Although prior studies have found…
Abstract Number: 780 • ACR/ARHP Annual Meeting 2013
Serious Infection Rates Among Patients With Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants
Candace H. Feldman¹, Linda T. Hiraki², Francisco M. Marty³, Wolfgang C. Winkelmayer⁴, Jessica M. Franklin⁵, Daniel H. Solomon^6,7, Seoyoung C. Kim⁸ and Karen H. Costenbader⁹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ³Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ⁴Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁷Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁸Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are among the leading causes of hospitalization and mortality in patients with systemic lupus erythematosus (SLE); approximately 50% have a serious infection during…

Abstracts tagged "medication and systemic lupus erythematosus (SLE)"

Apremilast in Patients with Lupus Rashes

Poor Adherence to Medications for Systemic Lupus Erythematosus Predicts Higher Health Care Utilization in U.S. Medicaid Beneficiaries

Serious Infection Rates Among Patients With Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants